Skip to content

VITALISE - intervention to promote lifestyle change in non-alcoholic fatty liver disease

Assessing the feasibility of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease (VITALISE- interVention to promote lIfesTyle change in non-Alcoholic fatty LIver diseaSE)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN12893503
Enrollment
35
Registered
2022-08-30
Start date
2022-11-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease (NAFLD) Digestive System

Interventions

Patients will be given a personal login for the VITALISE programme and will have continuous access for a 6-month time period prior to their follow-up appointment with a hepatologist. Patients will be

Sponsors

Newcastle upon Tyne Hospitals NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and over 2. Clinical diagnosis of NAFLD following review by a hepatologist within the last 6 months 3. Willing and able to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Decompensated NASH cirrhosis (Child Pugh score = 7) 2. Diagnosed/previous eating disorder or purging 3. Excessive alcohol consumption (>14 units/week for females; >21 units/week for males) 4. Known cancer (except skin cancer) 5. Myocardial infarction within 6 months or uncontrolled cardiovascular disease 6. Pregnant/considering pregnancy 7. Inability to understand written and verbal English

Design outcomes

Primary

MeasureTime frame
Criteria used to judge the feasibility of progressing to a larger scale evaluation: 1. Total number of patients recruited per month measured using data from a screening log over 6 months 2. Percentage of recruited patients who log in measured using data from the VITALISE digital platform during their 6-month intervention 3. Percentage of patients who logged in to VITALISE and provide follow-up data logged during the follow-up visit at 6 months These criteria aim to retain a sufficient sample size to determine acceptability and feasibility.

Secondary

MeasureTime frame
To determine whether acceptability and feasibility lead to changes in clinical outcomes, including: 1. Body weight 2. HbA1C 3. Liver enzymes 4. Liver stiffness 5. Blood pressure 6. Lipid profile All measured as part of standard care using standard methods at baseline and 6 months

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 11, 2026